Wellsheet Appoints Healthcare Veteran Ryan Sadlo to Help Health Systems Modernize EHR Systems to Address Physician Burnout

New Vice President of Growth to Accelerate Commercial Operations in the Public and Private Sector 

See more here


Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing 

– Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein. 

Efficacious in Syrian hamsters infected with SARS-CoV-2 (USA-WA1/2020) in both prophylactic and treatment schedules. 

– Neutralizes South Africa (B.1.351) and UK (B.1.1.7) in live virus testing; Brazil (P.1) and California (B.1.429, also containing B.1.427 mutations) in pseudovirus testing, all of which are CDC-designated “Variants of Concern.”

– Investigational New Drug (IND) Filing planned for late 2Q/early 3Q 2021.

See more here


Halo Labs Launches the Aura CL™ for Cell Therapy Product Quality

Aura CL is the first system specifically designed to quantify cell aggregates and ID cell vs non-cell contaminants    

See more here


Immunome Appoints Corleen Roche as Chief Financial Officer

– Seasoned biopharmaceutical executive with more than 30 years of corporate finance and business strategy experience –

See more here


Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder 

See more here


Immunome Appoints Dr. Dennis Giesing as Chief Development Officer

– Pharmaceutical industry veteran brings more than three decades of experience developing innovative therapies –

See more here


Ride Health to Provide Non-Emergency Transportation for Complex Patient Populations Across New York State Through Partnership With IMSNY

See more here


Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing

IMM-ONC-01: Advanced proprietary antibody against IL-38 into IND-enabling studies

Raised $44.9 million in gross proceeds in NASDAQ IPO 

Program updates expected in 2Q 2021

See more here


Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp. 

– Renovacor, Inc. has entered into a de􀁾nitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) – 
– Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under the ticker symbol “RCOR” – 
– The business combination is expected to be completed in the second quarter of 2021 – 

See more here